Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 15/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766179 | 0.90 | RBP4 (0.72) | RBP4TRPV1CA2CA9 | |
| SCHEMBL766186 | 0.83 | RBP4 (0.58) | RBP4SLC1A2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL766169 | 0.83 | RBP4 (0.69) | RBP4PKM | |
| SCHEMBL630989 | 0.82 | RBP4 (0.57) | RBP4SLC1A2 | |
| SCHEMBL766190 | 0.82 | RBP4 (0.65) | RBP4SLC1A2TRPV1CA2CA9 | |
| SCHEMBL766472 | 0.80 | RBP4 (0.54) | RBP4SLC1A2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL766200 | 0.78 | RBP4 (0.59) | RBP4SLC1A2GAA | |
| SCHEMBL630953 | 0.77 | RBP4 (0.54) | RBP4SLC1A2GAA | |
| SCHEMBL30996934 | 0.74 | RBP4 (1.00) | RBP4 | |
| SCHEMBL630501 | 0.74 | RBP4 (1.00) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | RBP4 1/4885SLC1A2 2272/4885CYP1A2 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.